Skip to content
WorldBrand.AI

Aurobindo Pharma controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile2 entries

  1. 2020

    Aurobindo Pharma and others sued over alleged metformin contamination concealment

    Lawsuit filed

    MSP Recovery filed a class action in a U.S. court against Aurobindo Pharma and other drug makers, alleging concealment of information about the cancer-causing agent NDMA in metformin. The article reports that Valisure's tests found NDMA in metformin produced by Aurobindo and Heritage, while also noting that Aurobindo passed the FDA test for NDMA presence.

    Source excerpt

    • Valisures tests revealed that the metformin produced by Aurobindo and Heritage were contaminated with NDMA with levels between 37 and 266 ng per tablet.
    • A class action suit has been filed against some drug manufacturers, including Aurobindo Pharma Ltd. and Emcure Pharmaceuticals, in a U.S. court for allegedly concealing facts about a cancer-causing agent, N- nitrosodimethylamine presence in metformin medicine.
    • Florida-based law firm MSP Recovery filed the petition on April 3 in the U.S. District Court for the Southern District of Florida on behalf of similarly-situated healthcare insurers to recover payments unlawfully induced by the drug makers- Aurobindo Pharma, Aurolife Pharma, LLC, and Heritage Pharmaceuticals LLC.
    Source

  2. 2020

    Astellas files patent-infringement complaint against pharmaceutical companies

    Lawsuit filed

    Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.

    Source excerpt

    • At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.
    • The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.
    • The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.
    Source